The Revlon/UCLA Breast Center practice guidelines for the treatment of breast disease

Cancer Journal from Scientific American

Volumn 2, Issue 1, 1996, Pages 2-15

  Love, Susan M ^a   McGuigan, Kimberly A ^b   Chap, Linnea ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

ADULT; AGE; AGED; ARTICLE; BREAST DISEASE; CLINICAL TRIAL; FEMALE; HUMAN; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE;

ADULT; AGE FACTORS; AGED; ANTINEOPLASTIC AGENTS; BREAST DISEASES; CLINICAL TRIALS; FEMALE; HUMANS; MIDDLE AGED; POSTMENOPAUSE; PREMENOPAUSE;

EID: 0008460761     PISSN: 10814442     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (77)

1. Woolf SH. Practice guidelines, a new reality in medicine. II: Methods of developing guidelines. Arch Intern Med 1992;152.
2. American Medical Association. Attributes to Guide the Development of Practice Parameters. Chicago: American Medical Association, 1994.
3. Donnegan WL. Evaluation of a palpable breast mass. N Engl J Med 1992;327:937-942.
4. Martelli G, Pilotti S, de Yoldi GC et al. Diagnostic efficacy of physical examination, mammography, fine needle aspiration, cytology (triple-test) in solid breast lumps: an analysis of 1708 cases. Tumori 1990;76:476.
5. Preece PE, Hughes LE, Mansel RE et al. Clinical syndromes of mastalgia. Lancet 1976;2:670.
6. Page JK, Mansel RE, Hughes LE. Clinical experience of drug treatments for mastalgia. Lancet 1985;2:373.
7. Allen SS, Froberg DC. The effect of decreased caffeine consumption on benign proliferative breast disease: a randomized clinical trial. Surgery 1986;101:720.4
8. London RS, Sundaram GS, Murphy L et al. The effect of vitamin E on mammary dysplasia: a double-blind study. Obstet Gynecol 1985;65:104.
9. Chaudary MA, Millis RR, Davies GC, Hayward JL. Nipple discharge: the diagnostic value of testing for occult blood. Ann Surg 1982;196:651-655.
10. Haagensen CD, Lane N, Lattes R et al. Lobular neoplasia (so-called lobular carcinoma in situ) of the breast. Cancer 1978;42:737.
11. Page DL, Dupont WD. Intraductal carcinoma of the breast. Cancer 1982;49:751.
12. Betsill WL, Rosen PP, Lieberman PH et al. Intraductal carcinoma: long-term follow-up after treatment by biopsy alone. J Am Med Assoc 1978;239:1863.
13. van de Vijver MJ, Peterse JL, Mooi WJ et al. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma in situ and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239-1245.
14. Lagios M. Management of non-invasive carcinoma of the breast. 15th Annual Symposium on Diagnostic Imaging, Providence, RI: Brown University, 1994.
15. Fisher B, Costantino J, Redmond C et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med 1993;328:1581.
16. Schnitt SJ, Abner A, Gelman R et al. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast conserving surgery and radiotherapy. Cancer 1994;74:1746.
17. Harris JR, Connolly JL, Schnitt SJ et al. The use of pathological features in selecting the extent of surgical resection necessary for breast cancer patients treated by primary radiation therapy. Ann Surg 1985;201:164.
18. Lindley R, Bulman A, Parsons P et al. Histological features predictive of an increased risk of early local recurrence after treatment of breast cancer by local tumor excision and radical radiotherapy. Surgery 1989;105:13.
19. Brenner M, Schnitt SJ, Connolly JL et al. The use of reexcision in primary radiation therapy for stage I and II breast carcinoma. Intl J Radiol Oncol Biol Phys 1985;11[suppl 1]:186.
20. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for T1a breast carcinoma: is it indicated? Cancer 1994;73:664.
21. Rosen PP, Groshen S, Saigo PE, Kinne DW, Hellman S. Pathologic prognostic factors in stage I (T1 N0 M0) and stage II (T1N1M0) breast carcinoma: a study of 644 patients with median follow-up of 18 years. J Clin Oncol 1989;7:1239-51.
22. Bonadonna G. Conceptual and practical advances in the management of breast cancer: the Karnofsky Memorial Lecture. J Clin Oncol 1989;7:1380-1397.
23. Mansour EG, Gray R, Shatila AH et al. Efficacy of adjuvant chemotherapy in high-risk node-negative breast cancer. N Engl J Med 1989;320:485-490.
24. Fisher B, Redmond C, Dimitrov NV et al. A randomized clinical trial evaluating sequential methotrexate and fluorouracil in the treatment of patients with node-negative breast cancer who have estrogen-receptor negative tumors. N Engl J Med 1989;320:473-478.
25. Early Breast Cancer Trialists' Collaborative Group. Systemic treatment of early breast cancer by hormonal, cytotoxic, or immune therapy: 133 randomized trials involving 31,000 recurrences and 24,000 deaths among 75,000 women. Lancet 1992;339:1-85.
26. Rosen PP, Groshen S, Kinne DW, Norton L. Factors influencing prognosis in node-negative breast carcinoma: analysis of 767 T1N0M0/T2N0M0 patients with long-term follow-up. J Clin Oncol 1993;11:2090-2100.
27. Gasparini G, Weidner N, Bevilacqua P et al. Tumor microvessel density, p53 expression, tumor size, and peritumoral lymphatic invasion are relevant prognostic markers in node-negative breast carcinoma. J Clin Oncol 1994;12:454-466.
28. Carter CL, Allen C, Henson DE et al. Relation of tumor size, lymph node status, and survival in 24,740 breast cancer cases. Cancer 1989;63:181-187.
29. Tabar L, Fagerberg G, Day NE et al. Breast cancer treatment and natural history: new insights from results of screening. Lancet 1992;339:412-414.
30. NIH Consensus Development Conference Statement. The NIH Consensus Development Conference on the Treatment of Early Stage Breast Cancer. Bethesda, Md: National Institutes of Health, 1990.
31. Stierer M, Rosen HR, Weber R, Marczell A, Kornek GV, Czerwenka E. Long-term analysis of factors influencing the outcome in carcinoma of the breast smaller than one centimeter. Surg Gynecol Obstet 1992;175:151-160.
32. McGuire WL, Clark GM. Prognostic factors and treatment decisions in axillary node-negative breast cancer. N Engl J Med 1992;326:1756-1761.
33. Clark GM, Dressier LG, Owens MA, Pounds G, Oldaker T, McGuire WL. Prediction of relapse or survival in patients with node-negative breast cancer by DNA flow cytometry. N Engl J Med 1989;320:627-633.
34. Fisher B, Redmond C, Fisher ER et al. Relative worth of estrogen or progesterone receptor and pathological characteristics of differentiation as indicators of prognosis in node-negative breast cancer patients: findings from National Surgical Adjuvant Breast and Bowel Project protocol B-06. J Clin Oncol 1988;6:1076-1087.
35. Rosen PP, Groshen S, Kinne DW. Prognosis in T2N0M0 stage I breast carcinoma: a 20-year follow-up study. J Clin Oncol 1991;9:1650-1661.
36. Tancini G, Bonadonna G, Valagussa P et al. Adjuvant CMF in breast cancer: comparative 5-year results of 12 versus 6 cycles. J Clin Oncol 1983;1:2-10.
37. Bartlett K, Eremin O, Hutcheon A. Adjuvant tamoxifen in the management of operable breast cancer: the Scottish trial. Report from the Breast Cancer Trials Committee, Scottish Cancer Trials Office (MRC), Edinburgh. Lancet 1987;2:171-175.
38. Fisher B, Constantino J, Redmond C et al. A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor positive tumors. N Engl J Med 1989;320:479-484.
39. Fisher B, Redmond C, Fisher ER et al. Ten-year results of a randomized clinical trial comparing radical mastectomy and total mastectomy with or without radiation. N Engl J Med 1985;312:674-681.
40. Valagussa P, Bonadonna G, Veronesei V. Patterns of relapse and survival following radical mastectomy. Analysis of 716 consecutive patients. Cancer 1978;41:1170-1178.
41. Jones SE, Moon TE, Bonadonna G et al. Comparison of different trials of adjuvant chemotherapy in stage II breast cancer using a natural history data base. Amer J Clin Oncol 1987;10:387-395.
42. Buzdar AU, Kau SW, Smith TL, Hortobagyi GN. Ten-year results of FAC adjuvant chemotherapy trial in breast cancer. Amer J Clin Oncol 1989;12:123-128.
43. Wood WC, Budman DR, Korzum AH et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-1259.
44. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-906.
45. Rivkin SE, Green S, Metch B et al. Adjuvant CMFVP versus melphalan for operable breast cancer with positive axillary nodes: 10-year results of a Southwest Oncology Group study. J Clin Oncol 1989;7:1229-1238.
46. Moliterni A, Bonadonna G, Valagussa P, Ferrari L, Zambetti M. Cyclophosphamide, methotrexate, and fluorouracil with and without doxorubicin in the adjuvant treatment of resectable breast cancer with one to three positive nodes. J Clin Oncol 1991;9:1124-1130.
47. Fisher B, Brown AM, Dimitrov NV et al. Two months of doxorubicin-cyclophosphamide with and without interval reinduction therapy compared with 6 months of cyclophosphamide, methotrexate, and fluorouracil in positive-node breast cancer patients with tamoxifen-nonresponsive tumors: results from the National Surgical Adjuvant Breast and Bowel Project B-15. J Clin Oncol 1990;8:1483-1496.
48. Fisher B, Redmond C, Wickerham DL et al. Doxorubicin-containing regimens for the treatment of stage II breast cancer: the National Surgical Adjuvant Breast and Bowel experience. J Clin Oncol 1989;7:572-582.
49. Levine MN, Gent M, Hryniuk WM et al. A randomized trial comparing 12 weeks versus 36 weeks of adjuvant chemotherapy in stage II breast cancer. J Clin Oncol 1990;8:1217-1225.
50. Carpenter J, Velez-Garcia E, Aran B et al. Prospective randomized comparison of cyclophosphamide, doxorubicin (adriamycin) and fluorouracil (CAF) versus cyclophosphamide, methotrexate, and fluorouracil (CMF) for breast cancer with positive axillary nodes: a Southeastern Cancer Study Group study. Proc Am Soc Clin Oncol 1991;9:45a.
51. Mathe G, Plagne R, Moric V et al. Consistencies and variations of observations during serial analyses of a trial of adjuvant chemotherapy in breast cancer. In: Salmon SE, ed: Adjuvant Therapy of Cancer V. Philadelphia, Grune and Stratton, 1987:271-280.
52. Buzzoni R, Bonadonna G, Valagussa P, Zambetti M. Adjuvant chemotherapy with doxorubicin plus cyclophosphamide, methotrexate, and flourouracil in the treatment of resectable breast cancer with more than three positive axillary nodes. J Clin Oncol 1991;9:2136-2140.
53. The Scottish Trial: Adjuvant tamoxifen in the management of operable breast cancer. Lancet 1987;2:171-175.
54. Fisher B, Redmond C, Legault-Poisson S et al. Postoperative chemotherapy and tamoxifen compared with tamoxifen alone in the treatment of positive-node breast cancer patients aged 50 years and older with tumors responsive to tamoxifen: results from the National Surgical Adjuvant Breast and Bowel Project B-16. J Clin Oncol 1990;8:1005-1018.
55. Goldhirsch A, Gelber RD. Adjuvant chemo-endocrine therapy o r endocrine therapy alone for postmenopausal patients: Ludwig Studies III and IV. In: Senn H, Goldhirsch A, Gelber RD, Osterwalder B, eds. Recent Results in Cancer Research: Adjuvant Therapy of Primary Breast Cancer. Berlin: Springer-Verlag, 1989:153-162.
56. Tormey DC, Gray R, Taylor SG et al. Postoperative chemotherapy and chemohormonal therapy in women with node-positive breast cancer. NCI Monogr 1986;1:75-80.
57. Rivkin S, Green S, Metch B et al. Adjuvant combination chemotherapy (CMFVP) versus tamoxifen (Tam) versus CMFVP + Tam for postmenopausal women with ER+ operable breast cancer and positive axillary lymph nodes: an intergroup study. J Clin Oncol 1994;12:2078-2085.
58. Peters WP. High-dose chemotherapy and autologous bone marrow support for breast cancer. In: DeVita VT, Hellman S, Rosenberg SA, eds: Important Advances in Oncology, 1991. Philadelphia: J.B. Lippincott, 1991:135-150.
59. Swain SM, Sorace RA, Bagley CS et al. Neoadjuvant chemotherapy in the combined modality approach of locally advanced non-metastatic breast cancer. Cancer Res 1987;47:3889-3894.
60. Hortobagyi GN. Comprehensive management of locally advanced breast cancer. Cancer 1990;66:1387-1391.
61. Smith IE, Walsh G, Jones A et al. High complete remission rates with primary neoadjuvant infusional chemotherapy for large early breast cancer. J Clin Oncol 1995;13:424-429.
62. Schwartz GF, Birchansky CA, Komarnicky LT. Induction chemotherapy followed by breast conservation for locally advanced carcinoma of die breast. Cancer 1994;73:362-369.
63. Peters WP, Ross M, Vrendenburgh JJ et al. High-dose chemotherapy and autologous bone marrow support as consolidation after standard-dose adjuvant therapy for high-risk primary breast cancer. J Clin Oncol 1993;11:1132-1143.
64. Ciatto S, Pacini P, Azzine V et al. Preoperative staging of primary breast cancer. A multicentric study. Cancer 1988;61:1038.
65. GIVO Investigators. Impact of follow-up testing on survival and health-related quality of life in breast cancer patients. A multicenter randomized, controlled trial. J Am Med Assoc 1994; 271:1587.
66. Borner M, Bacchi A, Goldhirsch A et al. First isolated locoregional recurrence following mastectomy for breast cancer: results of a phase III multicenter study comparing systemic treatment with observation after excision and radiation. J Clin Oncol 1994;12:2071.
67. Fisher B, Anderson S, Fisher ER et al. Significance of ipsilateral breast tumour recurrence after lumpectomy. Lancet 1991;338:327.
68. Clark G, Sledge GW, Osborne CK et al. Survival from first recurrence: relative importance of prognostic factors in 1,015 breast cancer patients. J Clin Oncol 1987;5:55-61.
69. Mick R, Begg CB, Antman K et al. Diverse prognosis in metastatic breast cancer: who should be offered alternative initial therapies? Breast Cancer Res Treat 1989;13:33-38.
70. Harris JR, Morrow M, Bonadonna G. Treatment of overt metastatic breast disease. In: DeVita VT, Hellman S, Rosenberg SA, eds. Cancer: Principles and Practice of Oncology. Philadelphia: J.B. Lippincott, 1993:1315-1323.
71. Henderson IC. Chemotherapy for advanced disease. In: Harris JR, Hellman S, Henderson IC et al, eds. Breast Diseases. Philadelphia: J.B. Lippincott, 1987:428-479.
72. Sledge G, Antman K. Progress in chemotherapy for metastatic breast cancer. Semin Oncol 1992;19:317.
73. Henderson IC: Endocrine therapy of metastatic breast cancer. In: Harris JR, Hellman S, Henderson IC et al, eds. Breast Diseases. Philadelphia, J.B. Lippincott:1991:559-603.
74. Eddy DA. High-dose chemotherapy with autologous bone marrow transplantation for the treatment of metastatic breast cancer. J Clin Oncol 1992;10:657-670.
75. Antman K, Ayash L, Elias A et al. A phase II study of high-dose cyclophosphamide, thiotepa, and carboplatin with autologous marrow support in women with measurable advanced breast cancer responding to standard-dose therapy. J Clin Oncol 1192;10:102-110.
76. Ingle JN, Krook JE, Green SJ et al. Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal patients with metastatic breast cancer. J Clin Oncol 1986;4:178-185.
77. Muss HB. Endocrine therapy for advanced breast cancer: a review. Breast Cancer Res Treat 1992;21:15-26.